Mylan Pharma rolls out muscle relaxant drug
AstraZeneca has received the US Food and Drug Administration's (FDA) approval for the use of Nexium I.V. (Esomeprazole sodium) for injection for the treatment of children 1 month to 17 years old who are suffering from gastroesophageal reflux disease (GERD) with erosive esophagitis.
Nexium I.V. is a proton pump inhibitor indicated for the treatment of GERD with erosive esophagitis in adults and pediatric patients greater than one month of age, when oral therapy is not possible or appropriate.
AstraZeneca Gastrointestinal Disorders executive director Marta Illueca said this approval represents an important contribution to an unmet medical need for infants in particular.
"While some reflux and regurgitation are normal in infants and may not require medical treatment, persistent GERD symptoms can be very uncomfortable and cause damage to the esophagus, just as they can in older patients," Illueca said.
May 18, 2011